Seminars in Nephrology
Volume 28, Issue 3 , Pages 306-317 , May 2008

Vasopressin Antagonists in Polycystic Kidney Disease

  • Vicente E. Torres, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Vicente E. Torres, MD, Division of Nephrology, Mayo Clinic, 200 First St SW, Rochester, MN 55905

References 

  1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287–1301
  2. Gunay-Aygun M, Avner ED, Bacallao RL, et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a First National Institutes of Health/Office of Rare Diseases conference. J Pediatr. 2006;149:159–164
  3. American PKD1 Consortium. Analysis of the genomic sequence for the autosomal dominant polycystic kidney disease (PKD1) gene predicts the presence of a leucine-rich repeat. Hum Mol Genet. 1995;4:575–582
  4. Hughes J, Ward CJ, Peral B, et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet. 1995;10:151–160
  5. International Polycystic Kidney Disease Consortium. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. Cell. 1995;81:289–298
  6. Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272:1339–1342
  7. Onuchic LF, Furu L, Nagasawa Y, et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet. 2002;70:1305–1317
  8. Ward CJ, Hogan MC, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet. 2002;30:259–269
  9. Xiong H, Chen Y, Yi Y, et al. A novel gene encoding a TIG multiple domain protein is a positional candidate for autosomal recessive polycystic kidney disease. Genomics. 2002;80:96–104
  10. Qian F, Germino FJ, Cai Y, et al. PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet. 1997;16:179–183
  11. Tsiokas L, Kim E, Arnould T, et al. Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci U S A. 1997;94:6965–6970
  12. Wang S, Zhang J, Nauli SM, et al. Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol. 2007;27:3241–3252
  13. Giamarchi A, Padilla F, Coste B, et al. The versatile nature of the calcium-permeable cation channel TRPP2. EMBO Rep. 2006;7:787–793
  14. Somlo S, Torres VE, Caplan MJ. Autosomal dominant polycystic kidney disease and inherited cystic disease. In:  Alpern RJ,  Hebert SC editor. The kidney. 4th ed.. 2007;p. 2283–2313
  15. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol. 2006;2:40–54
  16. Geng L, Burrow CR, Li HP, et al. Modification of the composition of polycystin-1 multiprotein complexes by calcium and tyrosine phosphorylation. Biochim Biophys Acta. 2000;1535:21–35
  17. Huan Y, van Adelsberg J. Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins. J Clin Invest. 1999;104:1459–1468
  18. Roitbak T, Ward CJ, Harris PC, et al. A polycystin-1 multiprotein complex is disrupted in polycystic kidney disease cells. Mol Biol Cell. 2004;15:1334–1346
  19. Chauvet V, Tian X, Husson H, et al. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest. 2004;114:1433–1443
  20. Low SH, Vasanth S, Larson CH, et al. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev Cell. 2006;10:57–69
  21. Hiesberger T, Gourley E, Erickson A, et al. Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca2+ and activation of protein kinase C. J Biol Chem. 2006;281:34357–34364
  22. Kaimori JY, Nagasawa Y, Menezes LF, et al. Polyductin undergoes notch-like processing and regulated release from primary cilia. Hum Mol Genet. 2007;16:942–956
  23. Pazour GJ, San Agustin JT, Follit JA, et al. Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol. 2002;12:R378–R380
  24. Ward CJ, Yuan D, Masyuk TV, et al. Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet. 2003;12:2703–2710
  25. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol. 2002;13:2508–2516
  26. McGrath J, Somlo S, Makova S, et al. Two populations of node monocilia initiate left-right asymmetry in the mouse. Cell. 2003;114:61–73
  27. Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet. 2003;33:129–137
  28. Praetorius HA, Spring KR. Bending the MDCK cell primary cilium increases intracellular calcium. J Membr Biol. 2001;184:71–79
  29. Anyatonwu GI, Estrada M, Tian X, et al. Regulation of ryanodine receptor-dependent calcium signaling by polycystin-2. Proc Natl Acad Sci U S A. 2007;104:6454–6459
  30. Koulen P, Cai Y, Geng L, et al. Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol. 2002;4:191–197
  31. Li Y, Wright JM, Qian F, et al. Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling. J Biol Chem. 2005;280:41298–41306
  32. Tsiokas L, Arnould T, Shu C, et al. Specific association of the gene product of PKD2 with the TRPC1 channel. Proc Natl Acad Sci U S A. 1999;96:3934–3939
  33. Qian Q, Hunter LW, Li M, et al. Pkd2 haploinsufficiency alters intracellular calcium in vascular smooth muscle cells. Hum Mol Genet. 2003;12:1875–1880
  34. Yang J, Zhang S, Zhou Q, et al. PKHD1 gene silencing may cause cell abnormal proliferation through modulation of intracellular calcium in autosomal recessive polycystic kidney disease. J Biochem Mol Biol. 2007;40:467–474
  35. Chabardes D, Firsov D, Aarab L, et al. Localization of mRNAs encoding Ca2+-inhibitable adenylyl cyclases along the renal tubule (Functional consequences for regulation of the cAMP content). J Biol Chem. 1996;271:19264–19271
  36. Dousa TP. Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int. 1999;55:29–62
  37. Houslay MD, Baillie GS. The role of ERK2 docking and phosphorylation of PDE4 cAMP phosphodiesterase isoforms in mediating cross-talk between the cAMP and ERK signalling pathways. Biochem Soc Trans. 2003;31:1186–1190
  38. Gattone VH, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323–1326
  39. Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10:363–364
  40. Wang X, Gattone VH II, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005;16:846–851
  41. Yamaguchi T, Nagao S, Kasahara M, et al. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis. 1997;30:703–709
  42. Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease (Understanding polycystic kidney disease: a systems biology approach). Kidney Int. 2003;64:1157–1162
  43. Hanaoka K, Guggino W. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol. 2000;11:1179–1187
  44. Yamaguchi T, Wallace DP, Magenheimer BS, et al. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem. 2004;279:40419–40430
  45. Sweeney WE, Chen Y, Nakanish K, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000;57:33–40
  46. Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A. 2006;103:5466–5471
  47. Leuenroth SJ, Okuhara D, Shotwell JD, et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci U S A. 2007;104:4389–4394
  48. O'Sullivan D, Torres V, Gabow P, et al. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1998;32:976–983
  49. Xu N, Glockner JF, Rossetti S, et al. Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. J Nephrol. 2006;19:529–534
  50. Li H, Findlay IA, Sheppard DN. The relationship between cell proliferation, Cl- secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int. 2004;66:1926–1938
  51. Magenheimer BS, St John PL, Isom KS, et al. Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+),K(+),2Cl(−) Co-transporter-dependent cystic dilation. J Am Soc Nephrol. 2006;17:3424–3437
  52. Torres VE, Sweeney WE, Wang X, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int. 2003;64:1573–1579
  53. Sweeney E, Donohoe DL, Avner ED. Inhibition of ErbB2 decreases c-SRC activity and ameliorates renal and biliary cystic abnormalities in the PCK rat. J Am Soc Nephrol. 2005;16:225A
  54. Sato Y, Harada K, Furubo S, et al. Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib. Am J Pathol. 2006;169:1238–1250
  55. Torres VE, Sweeney WE, Wang X, et al. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney Int. 2004;66:1766–1773
  56. Bukanov N, Smith LA, Klinger K, et al. Long lasting arrest of murine polycystic kidney disease with CDK inhibitor R-Roscovitine. Nature. 2006;444:949–952
  57. Omori S, Hida M, Fujita H, et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol. 2006;17:1604–1614
  58. Sweeney WE, Avner ED. Inhibition in autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol. 2006;17:778A
  59. Tao Y, Kim J, Schrier RW, et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol. 2005;16:46–51
  60. Wahl PR, Serra AL, Le Hir M, et al. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant. 2006;21:598–604
  61. Torres VE. Vasopressin antagonists in polycystic kidney disease. Kidney Int. 2005;68:2405–2418
  62. Mutig K, Paliege A, Kahl T, et al. Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am J Physiol Renal Physiol. 2007;293:F1166–F1177
  63. Yasuda G, Jeffries WB. Regulation of cAMP production in initial and terminal inner medullary collecting ducts. Kidney Int. 1998;54:80–86
  64. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res. 2001;51:372–390
  65. Liu L, Done SC, Khoshnoodi J, et al. Defective nephrin trafficking caused by missense mutations in the NPHS1 gene: insight into the mechanisms of congenital nephrotic syndrome. Hum Mol Genet. 2001;10:2637–2644
  66. Takei Y, Kawakoshi A, Tsukada T, et al. Contribution of comparative fish studies to general endocrinology: structure and function of some osmoregulatory hormones. J Exp Zoolog A Comp Exp Biol. 2006;305:787–798
  67. Liu W, Morimoto T, Kondo Y, et al. “Avian-type” renal medullary tubule organization causes immaturity of urine-concentrating ability in neonates. Kidney Int. 2001;60:680–693
  68. Beyenbach KW. Kidneys sans glomeruli. Am J Physiol Renal Physiol. 2004;286:F811–F827
  69. Danielsen H, Pedersen EB, Nielsen AH, et al. Expansion of extracellular volume in early polycystic kidney disease. Acta Med Scand. 1986;219:399–405
  70. Michalski A, Grzeszczak W. [The effect of hypervolemia on electrolyte level and and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease.]. Pol Arch Med Wewn. 1996;96:329–343
  71. Seeman T, Dusek J, Vondrak K, et al. Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res. 2004;53:629–634
  72. Devuyst O, Burrow CR, Smith BL, et al. Expression of aquaporins-1 and −2 during nephrogenesis and in autosomal dominant polycystic kidney disease. Am J Physiol. 1996;271:F169–F183
  73. Gattone VH, Maser RL, Tian C, et al. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet. 1999;24:309–318
  74. Yokoi H, Nagasaki H, Tachikawa K, et al. Adaptation to sustained high plasma vasopressin in water and electrolyte homeostasis in the rat transgenic for the metallothionein-vasopressin fusion gene. J Endocrinol. 2002;173:23–33
  75. Izumi Y, Nakayama Y, Mori T, et al. Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway. Am J Physiol Renal Physiol. 2007;292:F1418–F1426
  76. Bernat A, Hoffmann P, Dumas A, et al. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J Pharmacol Exp Ther. 1997;282:597–602
  77. Ali F, Guglin M, Vaitkevicius P, et al. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67:847–858
  78. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006;69:2124–2130
  79. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319–1331
  80. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297:1332–1343
  81. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112
  82. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860–867
  83. Wang S, Gattone VH, Somlo S, et al. Effectiveness of OPC-41061 on polycystic kidney disease development in Pkd2WS25/-. J Am Soc Nephrol. 2005;16:361A
  84. Gattone VH, Kinne Q, Torres VE. Efficacy of OPC-41061 in the treatment of murine nephronophthisis. J Am Soc Nephrol. 2005;16:138A
  85. Wang X, Wu Y, Ward CJ, et al. Vasopressin directly regulates cyst growth in the PCK rat. J Am Soc Nephrol. 2007;19:102–108
  86. Bouby N, Bankir L, Trinh-Trang-Tan MM, et al. Selective ADH-induced hypertrophy of the medullary thick ascending limb in Brattleboro rats. Kidney Int. 1985;28:456–466
  87. Bankir L, Fischer C, Fischer S, et al. Adaptation of the rat kidney to altered water intake and urine concentration. Pflugers Arch. 1988;412:42–53
  88. Nagao S, Kazuhiro N, Katsuyama M, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol. 2006;17:228–235
  89. Masyuk TV, Masyuk AI, Torres VE, et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology. 2007;132:1104–1116
  90. Chang MY, Parker E, El Nahas M, et al. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007;18:560–569
  91. Balster DA, O'Dorisio MS, Summers MA, et al. Segmental expression of somatostatin receptor subtypes sst(1) and sst(2) in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol. 2001;280:F457–F465
  92. Ishikawa S, Saito T, Kuzuya T. Reversal of somatostatin inhibition of AVP-induced cAMP by pertussis toxin. Kidney Int. 1988;33:536–542
  93. Ray C, Carney S, Morgan T, et al. Somatostatin as a modulator of distal nephron water permeability. Clin Sci (Lond). 1993;84:455–460
  94. Oishi R, Nonoguchi H, Tomita K, et al. Endothelin-1 inhibits AVP-stimulated osmotic water permeability in rat inner medullary collecting duct. Am J Physiol. 1991;261:F951–F956
  95. Hebert LA, Greene T, Levey A, et al. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis. 2003;41:962–971
  96. Cowley AW, Skelton MM, Kurth TM. Effects of long-term vasopressin receptor stimulation on medullary blood flow and arterial pressure. Am J Physiol. 1998;275:R1420–R1424
  97. Fernandes S, Bruneval P, Hagege A, et al. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology. 2002;143:2759–2766
  98. Nicco C, Wittner M, DiStefano A, et al. Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension. 2001;38:1143–1149
  99. Sauter D, Fernandes S, Goncalves-Mendes N, et al. Long-term effects of vasopressin on the subcellular localization of ENaC in the renal collecting system. Kidney Int. 2006;69:1024–1032
  100. Szentivanyi M, Park F, Maeda CY, et al. Nitric oxide in the renal medulla protects from vasopressin-induced hypertension. Hypertension. 2000;35:740–745
  101. Kocaman O, Oflaz H, Yekeler E, et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2004;43:854–860
  102. Wang D, Iversen J, Wilcox CS, et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int. 2003;64:1381–1388
  103. Argent NB, Burrell LM, Goodship TH, et al. Osmoregulation of thirst and vasopressin release in severe chronic renal failure. Kidney Int. 1991;39:295–300
  104. Bankir L, Ahloulay M, Bouby N, et al. Is the process of urinary urea concentration responsible for a high glomerular filtration rate?. J Am Soc Nephrol. 1993;4:1091–1103
  105. Bardoux P, Bichet DG, Martin H, et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant. 2003;18:497–506
  106. Bouby N, Bachmann S, Bichet D, et al. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol. 1990;258:F973–F979
  107. Bouby N, Hassler C, Bankir L. Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci. 1999;65:991–1004
  108. Sugiura T, Yamauchi A, Kitamura H, et al. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-b. Kidney Int. 1999;55:1800–1810
  109. Chapman AB, Torres VE JGJ, et al. A phase IIB pilot study of the safety and efficacy of tolvaptan, a vasopressin V2 receptor antagonist (V2RA) in patents with ADPKD. J Am Soc Nephrol. 2005;16:68A
  110. Grantham JJ, Chapman AB, Torres VE, et al. Acute and chronic osmostasis after vassopressin V2 receptor inhibition with Tolvaptan in ADPKD. J Am Soc Nephrol. 2005;16:361A
  111. Torres VE, Wang X, Ward CJ, et al. Urine aquaporin 2 and cyclic AMP responses to tolvaptan administration in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2005;16:361A
  112. Torres VE, Grantham JJ, Chapman AB, et al. Phase 2 open-label study to determine safety, tolerability and efficacy of split-dose Tolvaptan in ADPKD. Am J Physiol Renal Physiol. 2007;293:F1166–F1177

 Supported by the National Institutes of Health grant DK44863.

PII: S0270-9295(08)00050-8

doi: 10.1016/j.semnephrol.2008.03.003

Seminars in Nephrology
Volume 28, Issue 3 , Pages 306-317 , May 2008

Article Tools

* Image Usage & Resolution